Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk

Abstract We aimed to compare the (1) clinical outcomes including composite cardiovascular outcomes, cardiovascular death, and all-cause death, and (2) healthcare costs of using liraglutide and basal insulin as an initial treatment for patients with type 2 diabetes mellitus (T2DM) and high cardiovasc...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Wan-Chun Huang, Yen-Chou Chen, Chung-Hsuen Wu, Yu Ko
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/6429c9ea537d444484a6b4cbeca3e3a2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!